Building a Regulatory Marketing Review Process

The promotional review process is the single most important compliance mechanism in medical device marketing. Every brochure, every website page, every social media post, every sales presentation, every conference exhibit -- every piece of promotional content your company produces must go through a documented review and approval process before it reaches the public. This is not optional. It is a regulatory expectation, a legal necessity, and, when done right, a competitive advantage.

After 18 years of building and optimizing promotional review processes for medical device companies, I have seen what works and what does not. I have seen companies with review processes so slow and bureaucratic that their marketing is always six months behind the market. I have seen companies with review processes so informal that they are one warning letter away from a consent decree. And I have seen companies that have found the sweet spot -- rigorous enough to prevent compliance failures, efficient enough to keep marketing competitive. In this article, I am going to show you how to build the latter.

Why You Need a Formal Review Process

Let me start with the business case, because the compliance case is obvious. Yes, the FDA expects medical device companies to review promotional materials for regulatory compliance. Yes, failure to do so can result in warning letters, consent decrees, and worse. But the business case for a formal review process goes beyond avoiding trouble.

• Speed to market: A well-designed review process is actually faster than an informal one. When everyone knows what is expected, what the review criteria are, and what the timeline is, materials move through the pipeline more quickly than when every review is ad hoc.
• Consistency: A formal process ensures that all promotional materials meet the same standards, regardless of who created them or who reviewed them. This consistency builds brand credibility and reduces the risk of conflicting messages in the market.
• Institutional knowledge: The review process captures institutional knowledge about what claims are approved, what evidence supports them, and where the regulatory boundaries are. This knowledge survives personnel changes and prevents the company from having to re-learn compliance lessons.
• Audit readiness: A documented review process demonstrates to the FDA, to Notified Bodies, and to auditors that your company takes promotional compliance seriously. This documentation is your best defense in the event of regulatory scrutiny.
• Risk management: Every promotional material that goes through your review process is a risk that was managed. Every one that bypasses it is a risk that was not.

The Components of an Effective Review Process

An effective promotional review process has several core components. Here is the framework I use when building review processes for medical device companies:

Scope Definition

Define exactly which materials are subject to the review process. In my experience, the answer should be everything -- but "everything" needs to be specified so nothing falls through the cracks:

• Print materials: brochures, catalogs, sell sheets, posters, trade show graphics
• Digital materials: website content, blog posts, email campaigns, digital ads
• Social media: posts, stories, paid promotions, responses to user comments that reference product performance
• Sales materials: presentations, leave-behinds, demo scripts, competitive battle cards
• Video and multimedia: product videos, testimonial videos, webinar content, animations
• Press materials: press releases, media kits, interview talking points
• Conference materials: abstracts, podium presentations, poster presentations, exhibit materials
• Training materials: if they describe device use and performance (as distinct from purely technical installation guides)

I recommend erring on the side of inclusion. It is better to review a material that did not strictly need review than to miss one that did.

Review Criteria

Document the specific criteria reviewers should evaluate. This ensures consistency across reviewers and prevents subjective judgments from creeping into the process. The review criteria should include:

• Indication compliance: Are all claims within the device's cleared or approved indications for use?
• Claims substantiation: Is every clinical, safety, and performance claim supported by adequate evidence in the claims matrix?
• Fair balance: Is risk information presented with appropriate prominence alongside benefit claims?
• Truthfulness: Are all statements truthful and not misleading, including by omission?
• Net impression: Does the overall impression of the material accurately reflect the device's performance and risk profile?
• Competitive claims: Are any comparative claims substantiated and compliant with Lanham Act standards?
• Testimonials and endorsements: Are testimonials properly disclosed, within indications, and substantiated?
• Consistency: Is the material consistent with other current promotional materials and with the device's labeling?

Who Should Be on the Review Committee

The composition of your Promotional Review Committee (PRC) directly affects the quality and efficiency of the review. Include the right people, and you get thorough, balanced reviews. Include the wrong people -- or too many people -- and you get bottlenecks and turf wars.

Core Members (Required for Every Review)

• Regulatory Affairs: The regulatory reviewer is the most critical member. They assess compliance with FDA requirements, labeling alignment, and claims substantiation. This person must have a thorough understanding of the device's regulatory history, cleared labeling, and the current regulatory environment.
• Marketing: The marketing representative ensures that the review process serves marketing objectives while respecting regulatory boundaries. They advocate for messaging effectiveness and can propose alternative approaches when regulatory concerns arise.
• Legal: Legal review covers Lanham Act exposure, intellectual property issues, comparative advertising risks, FTC compliance, and general liability. Legal review is particularly important for comparative claims, testimonials, and materials with significant commercial impact.

Extended Members (As Needed)

• Medical Affairs / Clinical: For materials containing clinical data, study references, or medical claims, medical affairs review ensures clinical accuracy and appropriate interpretation of data. This reviewer should be a physician or scientist with relevant clinical expertise.
• Quality: For materials related to device labeling, IFU content, or quality claims, a quality representative ensures consistency with the quality management system.
• Sales Leadership: When sales materials or battle cards are being reviewed, sales leadership input ensures the materials will be useful in the field while remaining compliant.

Keep the core committee small -- three to four people is ideal for most reviews. Larger committees slow the process without proportionally improving the quality of reviews.

The Review Workflow

A well-designed workflow moves materials through the review process efficiently while ensuring thorough evaluation at each stage. Here is the workflow I recommend:

Stage 1: Initiation and Briefing

The marketing team submits the material for review along with a briefing document that includes the purpose of the material, the target audience, the distribution channels, the claims being made (mapped to the claims matrix), and any specific concerns or questions for the reviewers. A complete briefing reduces back-and-forth and accelerates the review.

Stage 2: Individual Review

Each reviewer on the PRC reviews the material independently against the documented review criteria. Independent review prevents groupthink and ensures that each reviewer applies their expertise without being influenced by others' opinions. Each reviewer documents their comments, questions, and required changes.

Stage 3: Committee Discussion

The PRC meets to discuss the material. This meeting resolves conflicting feedback, addresses questions raised during individual review, and reaches consensus on required changes. The discussion should focus on areas of disagreement -- if all reviewers agree, there is no need to discuss.

Stage 4: Revision

The marketing team revises the material based on PRC feedback. Significant revisions may require a second round of review. Minor revisions (typo corrections, formatting changes that do not affect claims or compliance) can be approved by a single designated reviewer.

Stage 5: Final Approval

All PRC members provide documented final approval of the material. This approval should be specific: "I approve version X.X of [material name] for distribution in [specified channels]." The approval, including the identity of each approver, the version approved, and the date, is recorded in the promotional review archive.

Stage 6: Distribution and Archiving

The approved material is distributed through the specified channels, and all review documentation -- drafts, comments, meeting notes, and final approval records -- is archived for the required retention period (typically matching your document retention policy, but no less than the device's market life plus six years).

Timeline Expectations: How Long Should Review Take

This is the question every marketing team asks, and the answer depends on the complexity of the material and the maturity of your review process. Here are the benchmarks I use with clients:

• Simple materials (standard claims, no clinical data, no comparative claims): 3-5 business days from submission to approval. Examples: trade show booth graphics, standard product sell sheets, routine social media posts using pre-approved messaging.
• Moderate materials (clinical data references, new claim language, testimonials): 7-10 business days. Examples: product brochures with clinical data, case study publications, KOL testimonial videos.
• Complex materials (new clinical claims, comparative advertising, major campaigns): 10-15 business days. Examples: comparative sales tools, new product launch campaigns, materials based on newly published clinical data.
• Pre-approved templates: 1-2 business days. If you have pre-approved messaging templates and the new material simply populates those templates with specific details, the review can be expedited significantly.

These timelines assume a well-functioning review process. If your reviews routinely take longer than these benchmarks, there is a process problem that needs to be diagnosed and fixed.

Common Process Failures and How to Fix Them

Having audited promotional review processes at dozens of medical device companies, I have identified the most common failure modes:

Failure 1: Bypass Culture

"We needed it yesterday, so we skipped review." This is the most dangerous process failure because it is the most tempting. When a trade show is three days away and the new graphics are not reviewed yet, the pressure to bypass the process is intense. The fix is cultural: leadership must establish and enforce the principle that no material goes to market without review. No exceptions. If the timeline is too tight, adjust the timeline -- do not skip the review.

Failure 2: Review Bottleneck

The process works, but it takes so long that marketing is always behind schedule. This is usually caused by too many reviewers, unclear review criteria (leading to extended discussions about subjective opinions), or insufficient reviewer capacity. The fix is to streamline: reduce the core committee to three people, document clear criteria, and allocate dedicated review time in reviewers' schedules.

Failure 3: Scope Gaps

The review process covers print materials but not social media. It covers brochures but not sales presentations. It covers new materials but not updates to existing materials. These gaps create compliance risks in the unreviewed channels. The fix is a comprehensive scope definition that captures all promotional materials across all channels, with no exceptions.

Failure 4: Outdated Claims Matrix

The claims matrix was created two years ago and has not been updated. New products have been launched, new clinical data has been published, and the competitive landscape has changed -- but the claims matrix still reflects the old reality. The fix is to assign ownership of the claims matrix and schedule mandatory reviews at least quarterly.

Failure 5: Inconsistent Standards

Different reviewers apply different standards, leading to inconsistent approvals. Material that one reviewer approved last month would have been rejected by this month's reviewer. The fix is documented review criteria, regular calibration sessions where reviewers discuss borderline cases, and a documented precedent file that records past review decisions for reference.

Digital Review Tools and Technology

The right technology can significantly improve the efficiency and auditability of your regulatory marketing review process. Here are the technology categories I recommend:

Promotional Review Software

Purpose-built promotional review platforms (sometimes called MLR software -- Medical, Legal, Regulatory) provide workflow management, annotation tools, version control, and audit trails specifically designed for promotional review. Solutions in this category include Veeva Vault PromoMats, Vodori Pepper Flow, and Red Nucleus. These tools are an investment, but for companies with high volumes of promotional materials, they pay for themselves in efficiency and auditability.

Project Management Tools

If purpose-built promotional review software is beyond your budget, general project management tools (Asana, Monday.com, Jira) can be configured to manage the review workflow. The key requirements are version control, commenting and annotation, approval tracking, and audit trail capabilities. Custom workflows can replicate much of what promotional review software does, though with less specialized functionality.

Document Management

Your promotional review archive must be maintained in a controlled document management system. SharePoint, Google Drive, or any other DMS can serve this purpose, but the system must support version control, access controls, and long-term retention. Every version of every promotional material -- along with its review comments, approvals, and supporting evidence -- must be retrievable for the life of the device plus six years.

Claims Database

A searchable claims database that links approved claims to their supporting evidence is the most valuable tool your review team can have. Some promotional review platforms include claims management functionality. If yours does not, a well-structured spreadsheet or database can serve the purpose. The database should be searchable by claim, by product, by evidence source, and by approval status.

Training Your Review Team

The quality of your review process is only as good as the people executing it. Training is essential, and it should cover both regulatory knowledge and process skills.

Regulatory Training

Every PRC member should receive training on FDA promotional regulations as they apply to medical devices, including fair balance requirements, claims substantiation standards, off-label promotion boundaries, and testimonial rules. This training should be refreshed annually and updated whenever significant regulatory guidance is issued.

Process Training

New PRC members should receive specific training on your company's review process, including the review criteria, the claims matrix, the workflow, and the documentation requirements. Shadow experienced reviewers during their first few reviews before participating independently.

Calibration Sessions

Hold periodic calibration sessions where PRC members review the same material independently and then compare their assessments. This identifies differences in how reviewers apply the criteria and provides an opportunity to align standards. I recommend calibration sessions quarterly for the first year and semi-annually thereafter.

Continuing Education

Encourage PRC members to stay current on FDA enforcement trends, industry best practices, and emerging compliance issues. Conference attendance (FDLI, RAPS, AdvaMed), webinars, and industry publications all contribute to maintaining a well-informed review team.

Expedited Review for Time-Sensitive Materials

Not every material can wait 10 days for review. Press releases responding to breaking news, social media posts about live events, and competitive responses all have time-sensitive components. A mature review process includes an expedited pathway for these situations.

Pre-Approved Messaging Libraries

Develop libraries of pre-approved messaging for common scenarios: conference posts, product announcements, disease awareness campaigns, and competitive responses. When a time-sensitive need arises, the marketing team can pull from pre-approved language rather than creating new content that requires full review.

Designated Rapid Reviewers

Identify one or two PRC members who are authorized to provide expedited review and approval for time-sensitive materials. These reviewers should be experienced enough to make sound compliance judgments quickly. Their approval authority in expedited mode should be documented and subject to audit.

Post-Publication Review

For real-time social media at live events, consider a hybrid approach: provide pre-approved templates and trained, authorized posters for real-time content, then conduct a thorough post-publication review within 24-48 hours. Any content that does not meet compliance standards is removed or revised. Document the post-publication review and any corrections made.

Measuring Review Process Performance

What gets measured gets managed. Track these metrics to evaluate and improve your review process:

• Cycle time: Average time from submission to approval, by material complexity category. Track trends over time -- is the process getting faster or slower?
• First-pass approval rate: Percentage of materials approved without revision on the first review. A low first-pass rate indicates that content creators need additional training or that the review criteria are unclear.
• Revision cycles: Average number of revision cycles before approval. More than two cycles suggests a communication problem between marketing and reviewers.
• Bypass rate: Percentage of materials that went to market without completing the review process. This should be zero. Any number above zero indicates a cultural or process problem.
• Reviewer utilization: Time each reviewer spends on reviews per week. If reviewers are overloaded, review quality and speed will suffer.
• Claims compliance rate: Percentage of submitted materials that contain only claims from the approved claims matrix. This measures how well content creators understand the boundaries.

Review these metrics quarterly and use them to identify trends, diagnose problems, and demonstrate the value of the review process to senior management. A well-functioning review process should show improving cycle times, high first-pass rates, and zero bypasses over time.

Special Considerations for Small and Mid-Size Companies

Large medical device companies have dedicated regulatory affairs departments, legal teams, and established review processes. Small and mid-size companies often have fewer resources and must build their review processes more efficiently. Here is how:

• Consolidate roles: In small companies, the same person may handle both regulatory review and legal review. This is acceptable as long as the person has competency in both areas. When in doubt, engage outside counsel for legal review of high-risk materials.
• Use templates and pre-approved messaging: Invest upfront in developing pre-approved messaging templates that can be reused across multiple materials. This reduces the volume of new materials requiring full review.
• Outsource selectively: Consider outsourcing regulatory review of complex materials (comparative claims, clinical data presentations) to consultants with specific expertise. Keep routine reviews in-house.
• Start simple and evolve: You do not need a six-figure software platform on day one. Start with a spreadsheet-based claims matrix, a shared drive for documentation, and a simple workflow (email-based if necessary). Upgrade to more sophisticated tools as your volume and complexity increase.
• Document from the beginning: Even if your process is informal, document it. A simple SOP that describes who reviews what, what criteria they apply, and how approvals are recorded is infinitely better than no documentation at all. If the FDA asks about your review process, "We have a documented SOP" is a much better answer than "We kind of just pass it around."

The key message for smaller companies is that the size of your review process should scale with the size of your promotional activities, but the existence of a review process is non-negotiable regardless of company size. Even a one-person company marketing a single product needs a documented review discipline.

Integrating the Review Process with Your Marketing Workflow

The review process should be integrated into your marketing workflow, not bolted on as an afterthought. Here is how to make review a natural part of how your marketing team works:

• Build review time into project timelines. Every marketing project plan should include review time as a scheduled milestone. If the brochure is due at the trade show on October 15, and review takes 10 business days, the material must be submitted for review by September 30 -- and that deadline should be in the project plan from day one.
• Involve reviewers early. Invite regulatory and legal reviewers to the creative brief meeting at the start of a project. Early input prevents late-stage surprises. A regulatory reviewer who sees the concept early can flag potential issues before the marketing team has invested time in development.
• Create feedback loops. After each review cycle, capture lessons learned. If the same types of issues keep getting flagged -- fair balance omissions, claims not in the matrix, unclear audience targeting -- address them through training and template updates rather than catching them repeatedly in review.
• Celebrate compliance. Recognize teams that achieve high first-pass approval rates and zero bypasses. Compliance is not glamorous, but recognizing the people who make it work builds the cultural reinforcement your process needs to survive.

A review process that is integrated into the marketing workflow does not feel like a burden -- it feels like a quality standard. And quality standards produce better work, not just safer work. The most effective medical device marketing I have seen comes from companies where compliance review makes the marketing better, not just compliant.